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Abstract
Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms with worldwide increasing incidence, high prevalence
and survival. Both the tumor itself and the systemic therapy may have an impact on patients’ nutrition. Malnutrition negatively
impacts on outcome in NETs patients. Moreover, it has been demonstrated that body mass index was a risk factor for NET
development and that metabolic syndrome was associated with worse prognosis in these patients. Of note, food could also
interact with the metabolism of oral target therapy and antineoplastic agents used for the treatment of progressive NETs.
Therefore, the nutritional assessment, based on body composition, and lifestyle modifications should be an integral component
of management of the NET patients. The nutrition care plans are an integral part of the multidisciplinary management team for
patients with NETs. Nutritionists with expertise in NETs can provide dietary approaches to improve the quality of life and
nutritional status during various therapeutic modalities used in patients with NETs. The aim of this review is to critically discuss
the importance of nutrition and body composition in patients with NETs.
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1 Introduction
Neuroendocrine tumors (NETs) are a heterogeneous group
of neoplasms, whose incidence has rapidly increased in the
last decades to 7.4 cases/100,000 [1–4]. NETs arise in any
tissue and organ, though they mainly affect the
gastroenteropancreatic (GEP) and bronchopulmonary tract
[5, 6], and show high survival rate and prevalence [1]. Age
of onset is considerably variable, but NETs more frequently
occur in the sixth decade, except when related to inherited
syndromes, as multiple endocrine neoplasia type 1 (MEN1)
or von Hippel Lindau disease [7–10]. Clinical manifestations
include specific syndromes related to hormone secretion and
local symptoms due to mass effect, but NETs may be diag-
nosed also as incidental findings. The GEP-NETs are
commonly characterized by hormone hypersecretion that
may induce different metabolic impairments. Nevertheless,
screening for hormone secretion is routinely not recommend-
ed in absence of specific signs or symptoms related to a spe-
cific syndrome [11], but early diagnosis of NET is crucial, as
they may negatively affect outcomes [12].
Although NETs have mainly an indolent course, they often
present with metastases, mainly hepatic metastases, already at
diagnosis [13]. In the long natural history, patients are often
treated with more therapeutic lines. Besides surgery, first line
therapy is usually represented by somatostatin analogs (SSA),
since they have an antiproliferative effect and are capable to
reduce hormone hypersecretion [14]. After progression with
SSA, targeted therapies (everolimus and sunitinib), chemo-
therapy, peptide receptor radionuclide therapy (PRRT) are
used in different sequences of treatment [15].
Both the tumor itself and the systemic therapy may have an
impact on patients’ nutrition [16]. The role of nutrition is
highly important in cancer patients, as malnutrition negatively
impacts on rates of complications, hospitalization, hospital
stay, costs and mortality [16, 17]. It has been demonstrated
that a poor nutritional status could influence the outcome of
patients with pancreatic NET [18] and predicts the tumor re-
sponse in patients receiving the transcatheter arterial
chemoembolization for liver metastases [19]. In order to
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prevent all these negative outcomes, the detection of malnu-
trition should be carried out with appropriate tools, early after
diagnosis, particularly in NETs, whose natural history is usu-
ally longer than in several cancer types [20].
Beyond the nutrition, convincing evidence suggest that the
excess of body fat represents a cause of several cancer [21]
and a meta-analysis showed that body mass index (BMI) was
the second relevant risk factor for NETs development after
family history of cancer in all investigated sites [22]. In a
series of non-functioning GEP NETs patients, we recently
demonstrated that metabolic syndrome was associated with
greater severity of the tumor, in terms of higher tumor size
and Ki67% proliferation index [23]. Conversely, the Bobesity
paradox^ suggests that higher BMI reduces mortality risk in
cancer patients, despite a greater risk of cancer associated with
higher BMI. According to a large database analysis of over
22.000 patients with abdominal NETs who underwent surgery
between 2009 and 2010, obesity seems to be a protective
factor against inpatient mortality [24]. This is a very debated
topic and definitely a detailed analysis of body composition
could clarify the relationship between cancer and obesity [25].
Data about nutrition in NETs are scattered [16, 18, 23] and
large epidemiological studies, as well as randomized clinical
trials are lacking. The aim of this review is to critical discuss
the role of nutrition and body composition on progression in
patients with NETs.
2 Search strategy and selection criteria
Relevant literature was searched in PubMed/Medline,
EMBASE and the Cochrane Library up to April 2018, using
at least one of the following specific keywords: neuroendo-
crine tumors, nutrition, Mediterranean Diet, obesity, lifestyle,
body mass index, bioelectrical impedance analysis, phase an-
gle, somatostatin analogs, everolimus, sunitinib, temozolo-
mide, food interaction. Boolean operators were used to im-
prove the precision of each search. Studies that were not in
English language, letters to editor, abstracts to conferences
and those without availability of full test were excluded. All
included studies were screened and discussed by the authors
until a general consensus was reached.
3 Nutrition and NETs
Several epidemiological studies support the theory that diet
plays an important role in the initiation, promotion and pro-
gression of cancers inWestern countries [26, 27]. In particular,
nutritional status in NETs, especially GEP, is deeply affected
by their excessive production of gastrointestinal hormones,
peptides, and amines, which can lead to malabsorption, diar-
rhea, steatorrhea, and altered gastrointestinal motility [23, 28].
Besides the tumor production of regulatory gastrointestinal
peptides, the surgical management of NETs that remove or
alter the anatomy of the gastrointestinal tract, or biotherapy
with synthetic SSA that suppress the secretion of pancreatic
enzymes as well as of gastrointestinal pancreatic hormones
and function, can lead to alteration of gastrointestinal secreto-
ry, motor, and absorptive functions, with both dietary and
nutritional consequences [23]. This points out how there is
an urgent need for consistent, evidence-based medicine nutri-
tional guidelines for patients with NETs.
In line with the American Cancer Society, it is recommend-
ed to eat at least five portions/servings (at least 400 g) of a
variety of non-starchy vegetables and fruit every day, limited
consumption of red and processed meat, that should be limited
to less than 500 g a week, limited consumption of alcohol, that
should be limited to no more than two drinks a day for men
and one drink per day for women, eat relatively unprocessed
cereals (grains) and/or legumes with every meal and limit their
intake of refined starchy foods [29]. An intake of less than 6 g
of salt (2.4 g sodium) a day was recommended, thereby
avoiding salt-preserved, salted or salty foods. In addition to
the above, energy-dense foods, as well as fast foods, should be
consumed sparingly and sugary drinks should be avoided
[29]. The constituents of these food groups seem to explain
the biochemical mechanisms by which diet can affect tumor
pathogenesis. Indeed, fruits and vegetables are important
sources of a wide variety of micronutrients and other bioactive
compounds, including antioxidants (such as vitamin C and E),
folate, carotenoids, glucosinolates, indoles, isothiocyanates,
protease inhibitors and phytochemicals (lycopene, phenolic
compounds, flavonoids etc.), which have been demonstrated
to exhibit anticancer properties [30, 31]. All these compounds
may act against cancer through different mechanisms, includ-
ing their antioxidant, anti-mutagenic and anti-proliferative
properties. In addition, modulation of the immune and endo-
crine systems and metabolic pathways have been proposed as
adjunctive mechanisms [30, 31].
Similar to other different cancers, the overall goals of nu-
tritional approaches for a NET patient is to develop individu-
alized nutrition care plans, to promote optimal nutritional sta-
tus, to evaluate the effectiveness of nutritional interventions,
to improve the quality of life of the patient during therapy,
depending also on whether or not the patient is symptomatic,
the stage of the disease, and the type of therapeutic manage-
ment. Thus, a skilled nutritionist should be part of the multi-
disciplinary health care team in NET management, adapting
the specific nutritional needs to the course of NETs. Despite
the pioneering work of Warner’s available at the Carcinoid
Cancer Foundation [32], up to now there are no dietary guide-
lines developed specifically for NETs.
For patients with newly diagnosed asymptomatic NETs, it
is useful to follow recommendations by the healthy diet based
on the 2015–2020 Dietary Guidelines Advisory Committee
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[33, 34]. However, due to the advancement of therapeutic and
diagnostic procedures, most NET patients, mainly GEP, are
cancer survivors. According to the American Cancer Society
[35], the major nutritional recommendation for all cancer sur-
vivors regarding lifestyle is to eat at least five servings of fruits
and vegetables per day [35]. In general, the patients with ad-
vanced cancer are often protein and fatty-acid deficient, with a
close link with the decrease in skeletal muscle mass [36] and
weight loss. Changes in food preferences and dietary habits
are also commonly noted in advanced cancer, thereby exacer-
bating nutrient insufficiencies [37]. In addition, nutrition sta-
tus may directly affect both tolerance to and effectiveness of
palliative chemotherapy treatments for solid tumors [38].
Considering the most common symptoms in NETs, which
includes diarrhea, abdominal pain, gas and bloating, flushing
and, to a lesser extent, fatigue, weakness, weight loss, and skin
rash, there are some key nutritional advices for this group of
patients. To prevent flushing it is mandatory to avoid spicy
foods and alcoholic beverages. To help the management of
diarrhea by the underlying endocrine tumors, NET patients
should substitute raw, high-fiber fruits and vegetables, thereby
introducing ripe bananas, pureed vegetables, cooked fruits,
rice, pasta, and potatoes. Additionally, jam or jelly on whole
grain bread should be used instead of cream cheese or butter
on white bread; clear broth soup instead of creamy soup;
crackers or pretzels in place of doughnuts and butter cookies;
electrolyte replacements drinks, such as Gatorade, instead of
carbonated soft drinks or fruit juice with pulp; and lactose-free
beverages and products instead of regular milk and dairy prod-
ucts [33]. Therapy with SSA [39], which suppress the gastro-
intestinal tract and pancreatic function, can lead to altered fat
and fat-soluble vitamin absorption [39], while systemic che-
motherapy and combination therapy with SSA, interferon,
mTOR inhibitors, or vascular endothelial growth factor inhib-
itors cause anorexia, weight loss, and liver function abnormal-
ities [40, 41].
An additional nutritional consideration in NET manage-
ment is to supplement the intake of rich foods in niacin.
Niacin deficiency, which can result from the increased trypto-
phan metabolism into serotonin, could lead to dermatitis, di-
arrhea, dementia, and pellagra. Supplementation with niacin
25 to 50 mg/day are recommended [42]. Furthermore, pancre-
atic enzymes, such as pancrease, creon, and ultrase, and sup-
plementations with fat-soluble vitamins A, D, E, and K, are
particularly recommended for patients with fat malabsorption
and steatorrhea, particularly related to therapy with SSA [43].
About the use of nutraceuticals or other dietary supplements
there is scant evidence, and as these products may interfere
with various chemotherapies, they should be used with
caution.
There is considerable evidence that the Mediterranean diet
(MD) represents a dietary pattern suitable in the prevention of
non-communicable diseases, including cancer [44–47]. A
meta-analysis including both cohort and case-control studies
investigating the effects of adherence to MD on overall cancer
risk evidenced that a high adherence to a MD is associated
with a significant reduction in the risk of overall cancer mor-
tality (10%), colorectal cancer (14%), prostate cancer (4%)
and aerodigestive cancer (56%) [48]. A few prospective co-
hort studies investigated the association between composition
of diet and cancer survival, reporting inconsistent results [49].
For example, several studies focused on the evaluation of the
relationship between survival and single nutrients rather than
dietary patterns [49, 50]. Moreover, it has been demonstrated
in volunteers recruited for the European Prospective
Investigation into Cancer and Nutrition (EPIC) study that the
adherence to a traditional Italian MD may help to prevent
weight gain and abdominal obesity [51]. The beneficial effects
of nutritional interventions promoting the Mediterranean food
pattern could be extended to NETs patients. Future well-
designed dietary intervention trials on larger population sam-
ples are needed to define specific dietary guidelines for NETs.
4 Body composition and NETs
There is convincing evidence that excess body fat is a cause of
several cancers [21]. Arnold et al. recently estimated that 3.6%
of all incident cancers in the world in 2013 were caused by
obesity [52]. A meta-analysis indicated that the increase in the
risk of developing cancer for every 5 kg/m2 increase in BMI
ranged from 9 to 56% [53, 54]. The BMI is inexpensive and
easily measured, and is considered a commonly used surro-
gate for evaluating adiposity. Nevertheless, BMI evaluates
excess weight rather than excess fat [55–57], as it does not
measure body fat directly, and poorly distinguishes between
fat mass and lean or bone mass [58]. A recently published
meta-analysis reported that, among risk factors for NETs, fam-
ily history of cancer is the most relevant risk factor for NET
development at all investigated sites, followed by BMI and
diabetes [22]. Nevertheless, NET-related weight loss due to
malnutrition is a frequently encountered yet underestimated
clinical event, with relevant prognostic and socioeconomic
implications for affected patients and caregivers [59].
Bioelectrical impedance analysis (BIA) and its derived
parameter phase angle (PhA) have been widely used in
different populations [60, 61]. BIA is a non-invasive di-
agnostic tool for the evaluation of body composition,
which measures resistance to an electrical current and ex-
trapolates fluid and fat compartments from this measure-
ment [62]. The parameters that can be measured include
hydration status (intracellular, extracellular and total water
content), body fat mass, and electrolyte composition,
which are essential in determining the overall health sta-
tus [63, 64]. Malnutrition-associated patterns of body
composition are increased extracellular mass (ECM),
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which is largely defined by extracellular water, and de-
creased body cell mass (BCM) [62, 65]. The PhA is an
indicator for cell membrane integrity, water distribution
between the intra- and extracellular spaces and prediction
of body cell mass, which is most commonly evaluated and
correlated with nutritional status and survival rate [66,
67]. Several studies indicate that the use of BIA and
PhA measures can benefit in the clinical management of
cancer patients in the prevention, diagnosis, prognosis and
in nutritional intervention [68]. The best use of BIA mea-
surements is the evaluation of individuals over time to
provide for longitudinal changes of PhA along with dis-
ease progression and treatment. In this context, it is im-
portant to remind that the evaluation of the beneficial
effect of therapeutic nutritional interventions should be
monitored by BIA and not only via BMI, because this
may be misleading in cases such as edema. Recently,
our group has reported a novel association between the
adherence to the Mediterranean diet and PhA, indepen-
dently of sex, age, and body weight, recommending the
nutrition assessment as good clinical practice in the clin-
ical settings [61]. Thus, BIA and PhA may be particularly
useful also to evaluate and predict outcomes related to
symptom management of patients with NETs, whose nu-
tritional status and the symptoms are clearly affected by
their tumours.
5 Nutritional assessment of patients
with NETs: the point of view of the nutritionist
The dietary evaluation in patients with cancer, in particular
macro- and micronutrient, plays a central role in the manage-
ment of these patients [69]. Disease-related malnutrition is
frequently encountered in cancer patients, with substantial
prognostic and socioeconomic implications [16]. A number
of different studies have evidenced that malnutrition in-
creases complication rates after oncological surgery, the
duration of hospitalization mostly due to a higher number
of infectious complications, and side effects of cytotoxic
treatment, and decreases response to treatment and the
quality of life on the other side, and ultimately a worse
prognosis in malnourished cancer patients [16]. Thus, both
regular nutritional assessment and nutritional therapy have
been recommended to cancer patients with active disease or
undergoing complete resection surgery to improve their
clinical outcome [16].
As well as in other oncological diseases, malnutrition is a
common problem in NET patients [16]. Few studies to date
have investigated the association among NETs, nutrition and
body composition [16, 18, 23]. Consequently, knowledge
about this association and the possible usefulness of a nutri-
tional treatment in NETs is still very limited [23, 28].
However, as in the majority of cases NET are characterized
by a relatively slowly growing neoplasms, NET patients pres-
ent only moderate ‘cachexia-inducing’ potential, which is also
reflected in the global good long-term prognosis.
Nevertheless, such as in other neoplasms, malnutrition is a
relevant clinical problem in NET patients, with an impact on
short- and long-term outcomes. Malnutrition might be an
underestimated problem in NETs patients, which should sys-
tematically be diagnosed by widely available standard
methods as nutritional status is an important independent
prognostic factor for NETs besides their proliferative capacity,
which influences treatment outcomes, treatment complica-
tions, quality of life and survival. The diagnosis of clinically
manifest malnutrition can be established by using simple
screening tools, such as the Nutritional Risk Screening
(NRS), in association with widely available serum surrogate
parameters ofmalnutrition (e.g. serum albumin levels) or mea-
sures of body composition, such as BIA, which can rather
easily be integrated into clinical routine. The direct measure-
ment of BIA parameters, such as PhA, represents a widely
available method among NET inpatient and outpatient nutri-
tion teams, as it provides an easily measureable, reproducible
and valid marker of malnutrition.
The specific role of malnutrition for prognosis and patient
management in NET patients has recently been reported by
Maasberg et al. [16] using clinical scores, such as Subjective
Global Assessment (SGA) or NRS, anthropometry, BIA, in
particular PhA, and serum surrogate parameters, including
albumin [16]. In this cross-sectional study the authors found
that up to one quarter of NET patients were at risk of malnu-
trition, as defined by SGA and NRS, in particular those with
high-grade (G3) tumors, with progressive disease and under-
going chemotherapy. In malnourished NET patients the dura-
tion of hospitalization was significantly longer, while long-
term overall survival was significantly reduced, thereby
confirming the role of malnutrition as an independent prog-
nostic factor for NET besides proliferative capacity [16].
Additionally, malnutrition was associated with significantly
poorer BIA parameters, and resulted in a decreased PhA and
an increased ECM to BCM ratio, indicating the loss of BCM
and an increase in ECM in malnourished NET patients com-
pared with well-nourished counterpart [16]. Among clinical
screening scores for the diagnosis of malnutrition, the NRS
has been proven to represent a valid and simple tool for iden-
tifying patients at high risk of malnutrition or actually mal-
nourished [16]. Of interest, the authors found that both the
SGA and NRS identify moderately to severely malnourished
NETs patients reliably.
Thus, BIA allows monitoring of nutritional status and body
compositional changes during the disease and treatment
course, helping set nutritional interventions, and it is recom-
mended also in NET patients as a method for malnutrition
assessment.
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6 Food interaction on oral target therapy
and antineoplastic agents
In patients with advanced progressive NETs, a targeted thera-
py with sunitinib or everolimus has been associated with a
significant improvement in progression-free survival (PFS)
over placebo [39]. The supposed long term treatment of
NET imposes to rule out any possible toxicity and oral admin-
istration of therapy significantly improves the quality of life
and allows home care, less interference with work and social
activities, as well as avoidance of painful injection [70].
However, an interaction between food and orally administrat-
ed medications including oral antineoplastic agents has been
shown. This is known as ‘food-drug interaction’, that can
change the absorption rate or interact with the metabolism of
specific drugs. In specific condition, this effect can be clini-
cally relevant, particularly to optimize medical treatment and
to avoid undesirable effects [71, 72]. Several mechanisms are
involved in the food-drug interaction, including food catego-
ries, the postprandial digestive system physiology, as well as
the pharmacokinetic or pharmacodynamic of the drug [71].
The most important mechanism involved in the pharmaco-
kinetic of oral antineoplastic agents, is the superfamily of the
cytochrome (CYP) P450 [73, 74]. Everolimus and sunitinib
are both administered orally and are predominantly metabo-
lized by the cytochrome P450 (CYP) 3A4, thus food that
affect the CYP 3A4 could influence their metabolism [72]. It
has been showed that grapefruit, a potent inhibitor of the
CYP3A4, could increase the risk of everolimus toxicity and
increase the plasma concentration of sunitinib and its active
metabolites [72]. Other food-inhibitors of the CYP3A4 are
camomile, cranberry, garlic, ginseng, green tea extract, pep-
per, resveratrol and soya [18]. A helpful website on this topic
has been provided by Dr. Flockhart at the Indiana University,
U.S.A., the ‘Cytochrom P450 Drug Interaction Table’, https://
drug-interactions.medicine.iu.edu/Main-Table.aspx. (https://
www.regionorebrolan.se/Files-sv/%C3%96rebro%20l%C3%
A4ns%20landsting/Arbete_utbildning/ST/ST-psykiatri/
inbjudan/Clinical-Table-CYP450.pdf).
Moreover, the absorption of the drugs depends on intestinal
enzymes and transporters, among which the P-glycoprotein
(Gp-P) that acts as a drug efflux pump and can limit the bio-
availability of some orally administered drugs, including the
inhibitors of tyrosine kinase, particularly everolimus but also
sunitinib [72]. High-fat meal could inhibit the Gp-P, blocking
the export of drugs with a consequent increased bioavailability
of the drug [71]. High-fat meal also reduced the concentration
time curve of everolimus [75].
CYP P450 enzymes play only a minor role in the metabo-
lism of temozolomide which is spontaneously hydrolyzed at
physiologic pH to its active species [76]. Therefore, food that
modified the normal pH of the gastrointestinal tract may in-
terfere with the pharmacokinetic of this drug and can reduce
rate and extend of medication absorbed by body, increasing
adverse effects [70].
In conclusion, grapefruit and other food that inhibit the
CYP34A, as well as high-fat meal, are preferred to be avoided
during the administration of everolimus and sunitinib, as well
as it should be preferred to avoid the administration of temo-
zolomide concomitant to a meal.
7 Conclusion
NETs have worldwide increasing incidence combined with
high survival rate and prevalence [1]. Surgery remains the
only curative treatment for early-stage disease [77], while so-
matostatin analogues represent the treatment of choice for
unresectable/advanced disease, followed by peptide receptor-
targeted radiotherapy and several drugs, such as targeted ther-
apy and chemotherapy [15, 77, 78].
Both the tumor itself and the systemic therapy may have an
impact on patients’ nutrition. Hormonal cosecretion such as
seen with the ectopic adrenocorticotropic hormone induced
Cushing’s syndrome can impact metabolic, nutritional, and
wound healing status [79]. However, data about nutrition in
NETs are scattered and large epidemiological studies, as well
as randomized clinical trials are lacking. A limited number of
studies demonstrated that malnutrition negatively impacts on
clinical outcome of NETs patients [16, 18] and that metabolic
syndrome was associated with greater severity of the NETs
[23]. Food could also interact with the metabolism of oral
targeted therapy and antineoplastic agents used for the
Fig. 1 Both the tumor itself and the systemic therapymay have an impact
on patients’ nutrition. The nutrition could interact with the oral target
therapy and antineoplastic agents used for the treatment of progressive
NETs. The nutritional assessment, based on body composition, should be
an integral component of management of the NETs patients. This
information is important either for Nutritionists and Endocrinologists
for increases the knowledge and on the potential usefulness of nutrition,
body composition evaluation and drugs interactions in NETs patients
with the aim to reduce the comorbidities and improve the quality of life
in these patients. Furthermore, these concepts suggests of a growing
cooperation between Nutritionists and Endocrinologists in the complex
management of the NETs patients
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treatment of progressive NETs [70, 71], Fig. 1. Finally, adher-
ence to the MD has been associated with the prevention of
several cancers [45–47] as well as with a significant reduction
in the risk of overall cancer mortality [48].
Therefore, the nutritional assessment, based on body
composition, and lifestyle modifications should be an inte-
gral component of management of the NETs patients [23,
28]. These Beasy^ concepts might be of strategic relevance
in terms of clinical efficacy and cost-effectiveness of the
newer drugs. The nutrition care plans are an integral part of
the multidisciplinary management team for patients with
NETs. Nutritionists with expertise in NETs can provide
dietary approaches to improve the quality of life and nutri-
tional status during various therapeutic modalities used in
patients with NETs. They can monitor these patients and
provide appropriate dietary changes to address the various
side effects of therapy. The goal of these recommendations
is to make NETs patients aware of beneficial dietary inter-
ventions. Achieving dietary-related goals includes an inte-
grated effort of a trained team that involves the NET pa-
tients in the decision-making process. Analogous to guide-
lines for managing patients with metabolic surgery [80,
81], it should be recommended that in the NET team a
leading role in providing nutrition care should be given
to skilled nutritionists, about the dietary interventions and
supporting nutrition and dietetic recommendations, and
NET patients should actively participate in the decision-
making process.
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